Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15079638 | 0.94 | FLT3 (0.80) | FLT3 | |
| SCHEMBL15079632 | 0.92 | FLT3 (0.82) | FLT3 | |
| SCHEMBL16222255 | 0.91 | FLT3 (0.86) | FLT3 | |
| SCHEMBL15079550 | 0.91 | FLT3 (1.00) | FLT3 | |
| SCHEMBL17706307 | 0.91 | FLT3 (0.86) | FLT3 | |
| SCHEMBL15079631 | 0.91 | FLT3 (0.81) | FLT3 | |
| SCHEMBL15079543 | 0.91 | FLT3 (1.00) | FLT3 | |
| SCHEMBL16222245 | 0.90 | FLT3 (0.84) | FLT3 | |
| SCHEMBL15079626 | 0.90 | FLT3 (0.84) | FLT3 | |
| SCHEMBL15079633 | 0.89 | FLT3 (0.85) | FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| EP-2763998-B1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2016-04-27 | — | — | EP | disclosed |
| US-9216997-B2 | Tri-heterocyclic derivatives, preparation process and uses thereof | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2015-12-22 | — | — | US | disclosed |
| US-9216997-B2 | Tri-heterocyclic derivatives, preparation process and uses thereof | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2015-12-22 | — | — | US | disclosed |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2014-11-06 | — | — | US | disclosed |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2014-11-06 | — | — | US | disclosed |
| WO-2013091502-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | MAP3K15, MAP3K1, MAP3K5 | FLT3 123/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | FLT3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.